Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
32.98
-1.76 (-5.05%)
Mar 31, 2025, 10:13 AM EDT - Market open

Crinetics Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Revenue
1.044.014.741.080.07
Upgrade
Revenue Growth (YoY)
-74.11%-15.28%339.43%1418.31%-94.05%
Upgrade
Cost of Revenue
240.16168.53130.2384.2657
Upgrade
Gross Profit
-239.12-164.51-125.49-83.18-56.93
Upgrade
Selling, General & Admin
99.7458.0942.3924.5318.03
Upgrade
Operating Expenses
99.7458.0942.3924.5318.03
Upgrade
Operating Income
-338.85-222.61-167.88-107.7-74.95
Upgrade
Interest & Investment Income
41.4413.444.320.160.99
Upgrade
Earnings From Equity Investments
-0.47-5.2-1.01--
Upgrade
Currency Exchange Gain (Loss)
----0.11-
Upgrade
Other Non Operating Income (Expenses)
-0.52-0.160.660.010.15
Upgrade
Pretax Income
-298.41-214.53-163.92-107.64-73.81
Upgrade
Net Income
-298.41-214.53-163.92-107.64-73.81
Upgrade
Net Income to Common
-298.41-214.53-163.92-107.64-73.81
Upgrade
Shares Outstanding (Basic)
8158523830
Upgrade
Shares Outstanding (Diluted)
8158523830
Upgrade
Shares Change (YoY)
39.11%11.71%35.24%26.24%25.95%
Upgrade
EPS (Basic)
-3.69-3.69-3.15-2.80-2.42
Upgrade
EPS (Diluted)
-3.69-3.69-3.15-2.80-2.42
Upgrade
Free Cash Flow
-229.81-171-116.86-89.02-62.21
Upgrade
Free Cash Flow Per Share
-2.85-2.94-2.25-2.32-2.04
Upgrade
Operating Margin
-32613.47%-5547.17%-3544.06%-9990.91%-105567.61%
Upgrade
Profit Margin
-28720.69%-5345.85%-3460.38%-9985.25%-103960.56%
Upgrade
Free Cash Flow Margin
-22118.77%-4261.03%-2466.98%-8258.26%-87623.94%
Upgrade
EBITDA
-336.07-221.51-166.9-106.78-74.01
Upgrade
D&A For EBITDA
2.791.10.980.920.95
Upgrade
EBIT
-338.85-222.61-167.88-107.7-74.95
Upgrade
Revenue as Reported
----0.07
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q